Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.

Abstract:

:This was an open-label, single-center, phase II study of 20 patients with multiple myeloma who were either proven poor mobilizers (n=10; group A) or predicted poor mobilizers (n=10; group B) and were planned for autologous hematopoietic SCT. The aim was to assess the safety and efficacy of plerixafor for stem cell mobilization and tumor cell contamination. The peripheral blood (PB) CD34+ cell count was generally very low pre- plerixafor and increased significantly post-plerixafor administration. Cumulative apheresis yields of > or =2 x 10(6) CD34+ cells/kg were observed in 7 of 10 patients (group A) and 8 of 10 patients (group B). Among the proven poor mobilizers, there was no evidence of tumor cell mobilization in the PB after G-CSF plus plerixafor treatment. Seventeen of 20 (85%) patients underwent transplantation. Neutrophil engraftment occurred at a median of 13 days for all patients. Platelet engraftment occurred at a median of 16 days and 19 days for all proven and predicted poor mobilizers, respectively. At 12 months, 12 of 17 patients had documented durable grafts, 3 of 17 patients died and 2 of 17 patients were lost to follow-up; but they had documented graft durability at the previous 3- and 6-month visit. The safety profile of plerixafor in all patients was consistent with previous reports.

journal_name

Bone Marrow Transplant

authors

Tricot G,Cottler-Fox MH,Calandra G

doi

10.1038/bmt.2009.130

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

63-8

issue

1

eissn

0268-3369

issn

1476-5365

pii

bmt2009130

journal_volume

45

pub_type

杂志文章
  • Cognitive and adaptive behavior 1 and 3 years following bone marrow transplantation.

    abstract::Children receiving a bone marrow transplant (BMT) are at risk for neuropsychological late effects because of potentially neurotoxic chemotherapy and total body irradiation. The goal of this study was to prospectively and longitudinally assess the intellectual and adaptive functioning of children receiving a BMT. This ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700699

    authors: Kramer JH,Crittenden MR,DeSantes K,Cowan MJ

    更新日期:1997-03-01 00:00:00

  • Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplant

    abstract::On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0451-2

    authors: Kansagra AJ,Frey NV,Bar M,Laetsch TW,Carpenter PA,Savani BN,Heslop HE,Bollard CM,Komanduri KV,Gastineau DA,Chabannon C,Perales MA,Hudecek M,Aljurf M,Andritsos L,Barrett JA,Bachanova V,Bonini C,Ghobadi A,Gill SI,Hi

    更新日期:2019-11-01 00:00:00

  • Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.

    abstract::Hepatic acute GvHD (aGvHD) is associated with high mortality owing to poor response to immunosuppressive therapy. The pathogenesis of hepatic aGvHD differs from that of other lesions, and specific risk factors related to pre-transplant liver conditions should be determined. We conducted a cohort study by using a Japan...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2015.205

    authors: Arai Y,Kanda J,Nakasone H,Kondo T,Uchida N,Fukuda T,Ohashi K,Kaida K,Iwato K,Eto T,Kanda Y,Nakamae H,Nagamura-Inoue T,Morishima Y,Hirokawa M,Atsuta Y,Murata M,GVHD working group of the Japan Society for Hematopoietic Ce

    更新日期:2016-01-01 00:00:00

  • Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD.

    abstract::The efficacy of posttransplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) in controlling GVHD has been previously reported. We aim to study the safety and efficacy of the use of dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning regimen allo-HSCT in 270 patients w...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0813-9

    authors: Salas MQ,Prem S,Atenafu EG,Datt Law A,Lam W,Al-Shaibani Z,Loach D,Kim DDH,Michelis FV,Lipton JH,Kumar R,Mattsson J,Viswabandya A

    更新日期:2020-09-01 00:00:00

  • Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution.

    abstract::A total of 11 high-risk Korean acute myeloid leukemia (AML) patients received stem cell transplantation from human leukocyte antigen (HLA) haploidentical donors. Specifically, for eight patients with 2-3 mismatched antigens and bidirectional vectors, we used a newly designed conditioning regimen that consists of total...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704900

    authors: Kim HJ,Min WS,Kim YJ,Kim DW,Lee JW,Kim CC

    更新日期:2005-05-01 00:00:00

  • The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue.

    abstract::The study was designed to determine whether the number of CD34+/CD33- cells given at autologous peripheral blood stem cell (PBSC) rescue after intensive therapy for cancer was a better predictor of platelet engraftment than the total number of CD34+ cells infused. Comparison between the total number of CD34+ cells/kg ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701368

    authors: Millar BC,Millar JL,Shepherd V,Blackwell P,Porter H,Cunningham D,Judson I,Treleaven J,Powles RL,Catovsky D

    更新日期:1998-09-01 00:00:00

  • Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation.

    abstract::In a study of 63 allogeneic and autologous bone marrow transplants, patients were randomized to receive the IgM and IgA enriched intravenous immunoglobulin (IVIG) preparation (Pentaglobin). Pentaglobin has been postulated to have anti-endotoxin properties and one of the aims of the study was to measure endotoxin level...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Poynton CH,Jackson S,Fegan C,Barnes RA,Whittaker JA

    更新日期:1992-06-01 00:00:00

  • Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.

    abstract::Nine patients with advanced Hodgkin's lymphoma (HL) who had undergone allogeneic stem cell transplantation (allo-SCT) received donor leukocyte infusions (DLIs) for treatment of persistent or progressive disease (PD). A total of 15 DLIs were performed, with four patients receiving more than one DLI. In four patients, p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704621

    authors: Anderlini P,Acholonu SA,Okoroji GJ,Andersson BS,Couriel DR,De Lima MJ,Donato ML,Khouri IF,Giralt SA,Ueno NT,Champlin RE

    更新日期:2004-09-01 00:00:00

  • Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s.

    abstract::There is substantial progress in preventing and treating cytomegalovirus (CMV) infections and CMV-related disease after allogeneic bone marrow transplantation. In CMV-seronegative recipients, use of CMV-seronegative blood products eliminates most CMV infections. Effective prophylaxis for CMV-seropositive recipients is...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Winston DJ,Gale RP

    更新日期:1991-07-01 00:00:00

  • Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR.

    abstract::Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.84

    authors: Imahashi N,Suzuki R,Fukuda T,Kakihana K,Kanamori H,Eto T,Mori T,Kobayashi N,Iwato K,Sakura T,Ikegame K,Kurokawa M,Kondo T,Iida H,Sakamaki H,Tanaka J,Kawa K,Morishima Y,Atsuta Y,Miyamura K

    更新日期:2013-01-01 00:00:00

  • Autologous peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma with extensive bone marrow necrosis.

    abstract::A patient with malignant lymphoma, large cell type and extensive bone marrow necrosis at presentation is reported. Bone marrow necrosis persisted even after a complete remission was induced with standard chemotherapy. Because of this adverse prognostic factor, circulating stem cells were collected and reinfused follow...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700786

    authors: Khan AM,Yamase H,Tutschka PJ,Bilgrami S

    更新日期:1997-05-01 00:00:00

  • Characterization of CD34+ subsets derived from bone marrow, umbilical cord blood and mobilized peripheral blood after stem cell factor and interleukin 3 stimulation.

    abstract::We characterized CD34+ cells purified from bone marrow (BM), mobilized peripheral blood (PB) and cord blood (CB) and we tried to establish correlations between the cell cycle kinetics of the CD34+CD38- and CD34+CD38+ subpopulations, their sensitivity to SCF and IL-3 and their expression of receptors for these two CSFs...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702145

    authors: De Bruyn C,Delforge A,Lagneaux L,Bron D

    更新日期:2000-02-01 00:00:00

  • Matched-related allogeneic stem cell transplantation in Saudi patients with Fanconi anemia: 10 year's experience.

    abstract::Allogeneic SCT is curative for bone marrow failure in Fanconi anemia (FA) patients but the optimal conditioning regimen is undetermined. We report here our experience with 56 FA patients who underwent allogeneic matched related SCT. The conditioning regimen varied according to time of SCT and disease status at SCT; 22...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.114

    authors: Ayas M,Al-Jefri A,Al-Seraihi A,Elkum N,Al-Mahr M,El-Solh H

    更新日期:2008-08-01 00:00:00

  • Therapy decisions in leukemia.

    abstract::Complex factors determine how physicians select between alternative therapies. We conducted a survey of 352 leukemia experts to determine consensus regarding optimal treatment for leukemia and to identify factors correlated with therapy decisions. The study evaluated both general treatment policies and recommendations...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Atkinson KA,Horowitz MM,Sobocinski KA,Rimm AA,Bortin MM,Gale RP

    更新日期:1992-01-01 00:00:00

  • Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group Study.

    abstract::This study evaluated delivery of involved field radiotherapy (IFRT) with transplantation for lymphomas timed to minimise toxicity. Patients transplanted for lymphoma had infradiaphragmatic disease irradiated pre-transplant and supradiaphragmatic disease post transplant. A total of 31 patients were studied, with a medi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/sj.bmt.1704759

    authors: Wirth A,Prince HM,Wolf M,Stone JM,Matthews J,Gibson J,Macleod C,Szer J,Grigg A,To B,Roos D,Schwarer AP,Davis S,Australasian Leukaemia and Lymphoma Group.

    更新日期:2005-02-01 00:00:00

  • Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens.

    abstract::Serum concentrations of Anti-Müllerian hormone (AMH) and Inhibin B were used to assess potential fertility in survivors of childhood haematopoietic stem cell transplantation (HSCT) after three chemotherapy-conditioning regimens of differing intensity. Of 428 patients transplanted between 1990-2012 for leukaemia and im...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0866-9

    authors: Leiper A,Houwing M,Davies EG,Rao K,Burns S,Morris E,Laven J,van der Kooi AL,van den Heuvel Eibrink M,Nussey S

    更新日期:2020-10-01 00:00:00

  • High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors.

    abstract::We report seven patients with germ cell tumors which either recurred following a minimum of two regimens of platinum-based chemotherapy or were refractory to cisplatin. The patients were treated with one or two courses of high dose carboplatin (CBDCA) and etoposide (VP-16) plus ifosfamide (IFX) with mesna uroprotectio...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Broun ER,Nichols CR,Tricot G,Loehrer PJ,Williams SD,Einhorn LH

    更新日期:1991-01-01 00:00:00

  • Circulating stem cell autografts.

    abstract::The role of autologous bone marrow transplantation in the treatment of malignant disease is currently being evaluated. The peripheral blood represents an alternative source of haemopoietic progenitors and the use of circulating rather than bone marrow stem cells permits autografting in patients with infiltrated bone m...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Bell AJ,Hamblin TJ,Oscier DG

    更新日期:1986-12-01 00:00:00

  • Risk of relapse in patients receiving azithromycin after allogeneic HSCT.

    abstract::Following publication of the ALLOZITHRO trial, the FDA released a safety announcement warning that azithromycin should not be given long-term to prevent BOS in patients with a blood or lymph cancer who have undergone allogeneic HSCT. Our site typically initiated azithromycin when patients were diagnosed with BOS post-...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01095-8

    authors: Kutzke JL,Merten JA,Taraba JL,Mara KC,Shah MV,Hashmi SK,Patnaik MM,Litzow MR,Hogan WJ,Alkhateeb HB

    更新日期:2020-10-31 00:00:00

  • Early infections in patients undergoing bone marrow or blood stem cell transplantation--a 7 year single centre investigation of 409 cases.

    abstract::Infections are a major cause of morbidity and mortality in patients undergoing high-dose therapy and subsequent autologous or allogeneic haemopoietic stem cell transplantation, despite the change from topical to systemic anti-infection prophylaxis and the introduction of growth factors and new antimicrobial drugs. We ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701614

    authors: Krüger W,Rüssmann B,Kröger N,Salomon C,Ekopf N,Elsner HA,Kaulfers PM,Mack D,Fuchs N,Dürken M,Kabisch H,Erttmann R,Zander AR

    更新日期:1999-03-01 00:00:00

  • Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.

    abstract::The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705712

    authors: Smith SD,Bolwell BJ,Rybicki LA,Brown S,Dean R,Kalaycio M,Sobecks R,Andresen S,Hsi ED,Pohlman B,Sweetenham JW

    更新日期:2007-08-01 00:00:00

  • Vaginal stenosis following allogeneic bone marrow transplantation for acute myeloid leukaemia.

    abstract::We report the unusual complication of vaginal stenosis occurring after allogeneic bone marrow transplantation (BMT) for leukaemia. This was in all likelihood a manifestation of chronic graft-versus-host disease (cGVHD), although the patient has no other stigmata of this and suffered little acute graft-versus-host dise...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701603

    authors: DeLord C,Treleaven J,Shepherd J,Saso R,Powles RL

    更新日期:1999-03-01 00:00:00

  • Evaluation of a monoclonal IgM antibody for purging of bone marrow for autologous transplantation.

    abstract::A monoclonal antibody of the IgM class, reacting with the CD9 (p24) antigen is described. The antibody (FMC27) is cytotoxic against cells of the common type of acute lymphoblastic leukaemia (c-ALL), giving killing at higher dilutions than an IgG antibody (FMC8) against the same antigen. FMC27 and FMC8 recognise differ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Zola H,Potter A,Neoh SH,Juttner CA,Haylock DN,Rice AM,Favaloro EJ,Kabral A,Bradstock KF

    更新日期:1987-02-01 00:00:00

  • Thrombotic microangiopathy following allogeneic bone marrow transplantation.

    abstract::Thrombotic microangiopathy is one of the complications of bone marrow transplantation and is related to other complications such as graft-versus-host disease, veno-occlusive disease, diffuse alveolar hemorrhage, and cytomegalovirus infection. Thrombotic microangiopathy occurred in three out of 12 patients who underwen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701890

    authors: Takatsuka H,Takemoto Y,Okamoto T,Fujimori Y,Tamura S,Wada H,Okada M,Kanamaru A,Kakishita E

    更新日期:1999-08-01 00:00:00

  • Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness.

    abstract::The introduction of hematopoietic growth factors (HGFs) offers new opportunities for autologous transplantation by facilitating and enriching collection of circulating progenitor cells from peripheral blood as a source of stem cell rescue. Substitution of peripheral blood progenitor cells (PBPC) from bone marrow in au...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Faucher C,le Corroller AG,Blaise D,Novakovitch G,Manonni P,Moatti JP,Maraninchi D

    更新日期:1994-12-01 00:00:00

  • Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.

    abstract::Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compared with historical controls (n = 157). Patients (n = 55) received fl...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0660-8

    authors: Shadman M,Maloney DG,Storer B,Sandmaier BM,Chauncey TR,Smedegaard Andersen N,Niederwieser D,Shizuru J,Bruno B,Pulsipher MA,Maziarz RT,Agura ED,Hari P,Langston AA,Maris MB,McSweeney PA,Storb R,Sorror ML

    更新日期:2020-01-01 00:00:00

  • Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients.

    abstract::As a consequence of the significantly larger inoculum of lymphoid cells present in peripheral blood stem cell (PBSC) harvests compared to bone marrow (BM), it is possible that autoPBSCT recipients may have an earlier and*or enhanced response to vaccines. Until data to confirm this become available, the European Blood ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703239

    authors: Gandhi MK,Egner W,Sizer L,Inman I,Zambon M,Craig JI,Marcus RE

    更新日期:2001-10-01 00:00:00

  • Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.

    abstract::Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell mobilization regimen of chemotherapy and G-CSF. Forty (26 multiple mye...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2009.119

    authors: Dugan MJ,Maziarz RT,Bensinger WI,Nademanee A,Liesveld J,Badel K,Dehner C,Gibney C,Bridger G,Calandra G

    更新日期:2010-01-01 00:00:00

  • Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma.

    abstract::Although infants with stage 4 neuroblastoma (NB) usually have a good prognosis, metastatic relapses after 1 year of age and amplification of the N-myc oncogene are established poor prognostic factors. In order to improve the survival of patients with such high-risk factors, we performed consolidation with a busulfan (...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702376

    authors: Valteau-Couanet D,Benhamou E,Vassal G,Stambouli F,Lapierre V,Couanet D,Lumbroso J,Hartmann O

    更新日期:2000-05-01 00:00:00

  • Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry.

    abstract::A questionnaire comprised of a series of clinical vignettes illustrating potential difficulties in diagnosis, grading and treatment of chronic graft-versus-host disease (GVHD) was completed by 65 bone marrow transplant physicians from 51 transplant centers worldwide. The concordance index (CI) for responses to each qu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Atkinson K,Horowitz MM,Gale RP,Lee MB,Rimm AA,Bortin MM

    更新日期:1989-05-01 00:00:00